|
GB0108591D0
(en)
*
|
2001-04-05 |
2001-05-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
GB0120347D0
(en)
|
2001-08-21 |
2001-10-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
EP1453516A2
(de)
*
|
2001-10-17 |
2004-09-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
|
|
US7399775B2
(en)
|
2001-12-27 |
2008-07-15 |
Daiichi Pharmaceutical Co., Ltd. |
β-amyloid protein production/secretion inhibitor
|
|
GB0223039D0
(en)
*
|
2002-10-04 |
2002-11-13 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
US7521481B2
(en)
|
2003-02-27 |
2009-04-21 |
Mclaurin Joanne |
Methods of preventing, treating and diagnosing disorders of protein aggregation
|
|
PL379466A1
(pl)
|
2003-06-30 |
2006-09-18 |
Daiichi Sankyo Company , Limited |
Heterocykliczne pochodne metylosulfonu
|
|
GB0323258D0
(en)
*
|
2003-10-04 |
2003-11-05 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
CA2578600A1
(en)
*
|
2004-06-16 |
2006-01-26 |
Wyeth |
Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
|
|
CN101103034A
(zh)
*
|
2005-01-14 |
2008-01-09 |
惠氏公司 |
抑制β-分泌酶的氨基-咪唑酮
|
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
|
WO2006123184A2
(en)
*
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Sulphonamido-substituted cyclohexyl sulphones for treatment of cancer
|
|
GB0513747D0
(en)
*
|
2005-07-06 |
2005-08-10 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
WO2007103114A2
(en)
*
|
2006-03-07 |
2007-09-13 |
The Brigham & Women's Hospital, Inc. |
Notch inhibition in the treatment or prevention of atherosclerosis
|
|
US9567396B2
(en)
|
2006-03-07 |
2017-02-14 |
Evonik Degussa Gmbh |
Notch inhibition in the prevention of vein graft failure
|
|
US8278345B2
(en)
|
2006-11-09 |
2012-10-02 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
|
WO2008076556A2
(en)
|
2006-11-15 |
2008-06-26 |
Massachusetts Eye & Ear Infirmary |
Generation of inner ear cells
|
|
ATE554085T1
(de)
|
2006-11-30 |
2012-05-15 |
Probiodrug Ag |
Neue inhibitoren von glutaminylcyclase
|
|
CA2676715A1
(en)
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of ad and related conditions
|
|
JP5930573B2
(ja)
|
2007-03-01 |
2016-06-15 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤の新規使用
|
|
WO2008128985A1
(en)
|
2007-04-18 |
2008-10-30 |
Probiodrug Ag |
Thiourea derivatives as glutaminyl cyclase inhibitors
|
|
US8377886B2
(en)
*
|
2007-09-14 |
2013-02-19 |
Albert Einstein College Of Medicine Of Yeshiva University |
Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
|
|
WO2009128057A2
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
|
AU2009239555A1
(en)
*
|
2008-04-23 |
2009-10-29 |
Merck Sharp & Dohme Corp. |
Cyclobutyl sulfones as Notch sparing gamma secretase inhibitors
|
|
WO2010060088A2
(en)
|
2008-11-24 |
2010-05-27 |
Massachusetts Eye & Ear Infirmary |
Pathways to generate hair cells
|
|
EP2393776B1
(en)
*
|
2009-02-06 |
2014-05-14 |
Merck Sharp & Dohme Corp. |
Novel trifluoromethylsulfonamide gamma secretase inhibitor
|
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
HAMMER OF ACT ACTIVITY
|
|
US20120129189A1
(en)
*
|
2009-07-17 |
2012-05-24 |
Chulan Kwon |
Methods of Controlling Cell Proliferation
|
|
PL2475428T3
(pl)
|
2009-09-11 |
2015-12-31 |
Probiodrug Ag |
Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
|
|
NZ598269A
(en)
*
|
2009-09-18 |
2014-12-24 |
Zalicus Pharmaceuticals Ltd |
Aryl sulphone derivatives as calcium channel blockers
|
|
CA2777043C
(en)
|
2009-10-14 |
2015-12-15 |
Schering Corporation |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
EP2493497A4
(en)
|
2009-11-01 |
2013-07-24 |
Brigham & Womens Hospital |
NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
|
|
ES2586231T3
(es)
|
2010-03-03 |
2016-10-13 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
|
MX2012010470A
(es)
|
2010-03-10 |
2012-10-09 |
Probiodrug Ag |
Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
|
|
US8541596B2
(en)
|
2010-04-21 |
2013-09-24 |
Probiodrug Ag |
Inhibitors
|
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
CN103068980B
(zh)
|
2010-08-02 |
2017-04-05 |
瑟纳治疗公司 |
使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
|
|
RU2745848C2
(ru)
|
2010-08-17 |
2021-04-01 |
Сирна Терапьютикс, Инк. |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
EP2686313B1
(en)
|
2011-03-16 |
2016-02-03 |
Probiodrug AG |
Benzimidazole derivatives as inhibitors of glutaminyl cyclase
|
|
WO2013059302A1
(en)
|
2011-10-17 |
2013-04-25 |
Nationwide Children's Hospital, Inc. |
Products and methods for aortic abdominal aneurysm
|
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
CA2884309A1
(en)
|
2012-09-07 |
2014-03-13 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
|
|
EP2892506B1
(en)
|
2012-09-07 |
2021-11-03 |
Massachusetts Eye & Ear Infirmary |
Treating hearing loss with the gamma-secretase inhibitor ly411575
|
|
CA2882950A1
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
SMT201700595T1
(it)
|
2012-11-28 |
2018-03-08 |
Merck Sharp & Dohme |
Composizioni e metodi per trattare il cancro
|
|
WO2014100065A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
US8859286B2
(en)
|
2013-03-14 |
2014-10-14 |
Viacyte, Inc. |
In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2015104343A1
(en)
*
|
2014-01-09 |
2015-07-16 |
Proyecto De Biomedicina Cima, S.L. |
New antifibrinolytic compounds
|
|
EP3166627A1
(en)
|
2014-07-11 |
2017-05-17 |
Genentech, Inc. |
Notch pathway inhibition
|
|
WO2016022776A2
(en)
|
2014-08-06 |
2016-02-11 |
Massachusetts Eye And Ear Infirmary |
Increasing atoh1 life to drive sensorineural hair cell differentiantion
|
|
EP3324965A4
(en)
|
2015-07-24 |
2019-07-03 |
Oncotracker, Inc. |
Gamma secretase modulators for the treatment of immune system dysfunction
|
|
WO2017096233A1
(en)
|
2015-12-04 |
2017-06-08 |
Massachusetts Eye And Ear Infirmary |
Treatment of hearing loss by inhibition of casein kinase 1
|
|
CN109219439B
(zh)
|
2016-01-29 |
2022-09-20 |
马萨诸塞眼科耳科诊所 |
内耳支持细胞的扩增和分化及其使用方法
|
|
KR102362222B1
(ko)
|
2016-05-16 |
2022-02-11 |
더 제너럴 하스피탈 코포레이션 |
폐 상피 공학에서 인간 기도 줄기 세포
|
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
|
EP3554502A4
(en)
|
2016-12-16 |
2021-01-06 |
Pipeline Therapeutics, Inc. |
METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
WO2019094312A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
WO2020016377A1
(en)
|
2018-07-19 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
|
CA3108388A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
WO2020033285A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
ES3022307T3
(en)
|
2019-12-17 |
2025-05-28 |
Merck Sharp & Dohme Llc |
Prmt5 inhibitors
|
|
ES3074517T3
(en)
|
2019-12-17 |
2026-07-21 |
Merck Sharp & Dohme Llc |
4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
|
|
EP4076460B1
(en)
|
2019-12-17 |
2026-01-21 |
Merck Sharp & Dohme LLC |
1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
|
|
EP4076459B1
(en)
|
2019-12-17 |
2026-04-29 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
WO2021195362A1
(en)
|
2020-03-26 |
2021-09-30 |
Seagen Inc. |
Methods of treating multiple myeloma
|
|
EP4244391A1
(en)
|
2020-11-16 |
2023-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
CN120225528A
(zh)
|
2022-09-02 |
2025-06-27 |
默沙东有限责任公司 |
依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途
|
|
KR20250079227A
(ko)
|
2022-10-25 |
2025-06-04 |
머크 샤프 앤드 돔 엘엘씨 |
엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
|
|
KR20250116773A
(ko)
|
2022-12-14 |
2025-08-01 |
머크 샤프 앤드 돔 엘엘씨 |
아우리스타틴 링커-페이로드, 제약 조성물, 및 그의 용도
|